The biopharmaceutical sector limped through August as its equities were hit by a sharp pullback until the very last trading day of the month, with the BioWorld Biopharmaceutical index recording a 4 percent jump to turn what was heading to be a negative period into a 2.2 percent increase in valuation. Up until Thursday, despite a stream of positive industry news, investors had been on the sidelines, perhaps remaining cautious about the prevailing uncertain broader market environment, which also kept the Nasdaq and Dow treading water.